



Ref. No.: MUM/SEC/130-10/2025-26

October 14, 2025

To,

The Manager  
Listing Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400 001

The Manager  
Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot C/1  
G Block, Bandra Kurla Complex,  
Mumbai – 400 051

**Scrip code: Equity (BSE: 540716/ NSE: ICICIGI)**

Dear Sir/Madam,

**Subject: Outcome of the Board Meeting held on Tuesday, October 14, 2025**

Pursuant to Regulation 30, 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that based on the recommendation of the Audit Committee, the Board of Directors of the Company, at their Meeting held today i.e. on Tuesday, October 14, 2025, approved Audited Financial Statements for the half-year ended September 30, 2025 and Audited Financial Results of the Company for the quarter and half-year ended September 30, 2025.

A copy of the Audited Financial Results for the quarter and half-year ended September 30, 2025, together with the Joint Statutory Auditors' Report thereon, in the prescribed format is enclosed herewith.

The Board also approved declaration and payment of interim dividend of ₹ 6.50/- per equity share i.e. at the rate of 65.0% of face value of ₹ 10/- each, for the financial year ended March 31, 2026. The interim dividend shall be paid to the equity shareholders of the Company, whose names appear in the Register of Members of the Company or in the records of Depositories as beneficial owners of the shares as on Thursday, October 23, 2025, being record date fixed for this purpose.

The Interim Dividend will be paid to the equity shareholders of the Company on or before Wednesday, November 12, 2025, subject to deduction of tax at source at applicable rate.

## **ICICI Lombard General Insurance Company Limited**

IRDA Reg. No. 115  
Mailing Address:  
Sixth floor- Interface 16,  
Office no 601 & 602,  
New linking Road, Malad  
west, Mumbai - 400064.

CIN: L67200MH2000PLC129408  
Registered Office:  
ICICI Lombard House, 414, Veer Savarkar Marg,  
Near Siddhi Vinayak Temple, Prabhadevi,  
Mumbai - 400 025.

You can contact us at  
Toll free No.: 1800 2666  
Email: customersupport@icicilombard.com  
Website: www.icicilombard.com



The Meeting of Board of Directors commenced at 3:20 p.m. and concluded at 5:30 p.m.

The above information will be made available on the website of the Company at [www.icicilombard.com](http://www.icicilombard.com).

You are requested to kindly take the same on your records.

Thanking you.

Yours Sincerely,

**For ICICI Lombard General Insurance Company Limited**

**Vikas Mehra**  
**Company Secretary**

**Encl. as above**

## **ICICI Lombard General Insurance Company Limited**

**IRDA Reg . No. 115**  
**Mailing Address:**  
Sixth floor- Interface 16,  
Office no 601 & 602,  
New linking Road, Malad  
west, Mumbai - 400064.

**CIN: L67200MH2000PLC129408**  
**Registered Office:**  
ICICI Lombard House, 414, Veer Savarkar Marg,  
Near Siddhi Vinayak Temple, Prabhadevi,  
Mumbai - 400 025.

**You can contact us at**  
Toll free No.: 1800 2666  
Email: [customersupport@icicilombard.com](mailto:customersupport@icicilombard.com)  
Website: [www.icicilombard.com](http://www.icicilombard.com)

**Walker Chandio & Co LLP***Chartered Accountants*

16<sup>th</sup> Floor, Tower III, One International Centre,  
S B Marg, Prabhadevi (W),  
Mumbai – 400013

**PKF Sridhar & Santhanam LLP***Chartered Accountants*

201, 2nd Floor, Center Point Building,  
Dr. BR Ambedkar Road,  
Parel, Mumbai - 400012

**Auditor's Report on Quarterly Financial Results and Year to Date Results of ICICI Lombard General Insurance Company Limited pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and IRDAI Circular reference: IRDAI/F&A/CIR/LFTD/027/01/2017 dated 30 January 2017****To The Board of Directors of  
ICICI Lombard General Insurance Company Limited**

We have audited the accompanying quarterly financial results of ICICI Lombard General Insurance Company Limited (the "Company") for the quarter ended 30 September 2025 and the year to date financial results for the period 1 April 2025 to 30 September 2025 (the "Results"), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including relevant circulars issued by the SEBI from time to time ("SEBI Listing Regulations") and Insurance Regulatory and Development Authority ("IRDAI" or "Authority") circular reference : IRDA /F&A /CIR/ LFTD/ 027 / 01/ 2017 dated January 30, 2017. These Results have been prepared on the basis of the condensed interim financial statements, which are responsibility of the Company's management and have been approved by the Board of Directors on 14 October 2025.

Our responsibility is to express an opinion on these Results based on our audit of such condensed interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard ("AS") - 25, "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 (the "Act") read with the Companies (Accounting Standard) Rules, 2021, as amended including the relevant provisions of the Insurance Act, 1938 as amended, the Insurance Regulatory and Development Authority of India Act, 1999 and other accounting principles generally accepted in India, to the extent considered relevant and appropriate for the purpose of the Results and which are not inconsistent with the accounting principles as prescribed in the Insurance Regulatory and Development Authority of India (Actuarial, Finance and Investment Functions of Insurers) Regulations, 2024 and orders/directions/circulars issued by the IRDAI, to the extent applicable.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the Results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as Results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these Results:

- i) are presented in accordance with the requirements of Regulation 33 of the SEBI Listing Regulations and IRDAI Circular reference number IRDA /F&A /CIR/ LFTD/ 027 / 01/ 2017 dated January 30, 2017 in this regard; and
- ii) give a true and fair view of the net profit and other financial information for the quarter ended 30 September 2025 as well as year to date results for the period 1 April 2025 to 30 September 2025.



**Walker Chandiook & Co LLP**  
Chartered Accountants

**PKF Sridhar & Santhanam LLP**  
Chartered Accountants

**Other Matter**

The actuarial valuation of liabilities in respect of Claims Incurred But Not Reported (the "IBNR"), Claims Incurred But Not Enough Reported (the "IBNER") and Premium Deficiency Reserve (the "PDR") is the responsibility of the Company's Appointed Actuary (the "Appointed Actuary"). The actuarial valuation of these liabilities, which are estimated using statistical methods as at 30 September 2025 has been duly certified by the Appointed Actuary and in his opinion, the assumptions considered by him for such valuation are in accordance with the guidelines and norms issued by the IRDAI and the Institute of Actuaries of India in concurrence with the IRDAI. We have relied upon the Appointed Actuary's certificate in this regard for forming our opinion on the valuation of liabilities for outstanding claims reserves and the PDR contained in the Results of the Company.

For **Walker Chandiook & Co LLP**  
Chartered Accountants  
Firm's Registration Number:  
001076N/N500013

**Sudhir N. Pillai**  
Partner  
Membership No. 105782



UDIN: 25105782BMLIFU8370

Place: Mumbai  
Date: 14 October 2025

For **PKF Sridhar & Santhanam LLP**  
Chartered Accountants  
Firm's Registration Number:  
003990S/S200018

**Dhiraj Kumar Birla**  
Partner  
Membership No. 131178



UDIN: 25131178BMLBXV1055

Place: Mumbai  
Date: 14 October 2025

**ICICI Lombard General Insurance Company Limited**

CIN: L67200MH2000PLC129408

Registered Office Address: ICICI Lombard House, 414, Veer Savarkar Marg,  
Near Siddhivinayak Temple, Prabhadevi, Mumbai-400025, Maharashtra  
IRDAI Registration No. 115 dated August 3, 2001

(Pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with IRDAI Circular reference : IRDA/F&A/CIR/LFTD/027/01/2017 dated 30.01.2017)

**Annexure-I  
Statement of Audited Results for the Quarter and year to date ended September 30, 2025**

(₹ in lakhs unless otherwise specified)

Sl. No.	Particulars	3 months ended / As at			Year to date ended / As at		Year ended / As at
		September 30, 2025 Audited	June 30, 2025 Audited	September 30, 2024 Audited	September 30, 2025 Audited	September 30, 2024 Audited	March 31, 2025 Audited
<b>OPERATING RESULTS</b>							
1	Gross Premiums written	705,886	805,255	694,830	1,511,141	1,487,935	2,825,774
2	Net Premium written	531,304	561,052	483,545	1,092,356	1,019,598	2,076,106
3	Premium Earned (Net)	565,165	513,609	502,557	1,078,774	952,945	1,980,020
4	Income from investments (net) <sup>2</sup>	89,893	94,274	84,625	184,167	169,082	315,590
5	Other income	3,209	453	(2,117)	3,662	(1,767)	(1,950)
6	<b>Total income (3 to 5)</b>	<b>658,267</b>	<b>608,336</b>	<b>585,065</b>	<b>1,266,603</b>	<b>1,120,260</b>	<b>2,293,660</b>
7	Commissions & Brokerage (net) <sup>3</sup>	101,277	94,075	84,472	195,352	164,920	383,803
8	Net commission <sup>3</sup>	101,277	94,075	84,472	195,352	164,920	383,803
Operating Expenses related to insurance business (a + b):							
9	(a) Employees' remuneration and welfare expenses	40,930	43,085	36,959	84,015	73,081	151,569
	(b) Other operating expenses	33,356	30,753	38,516	64,109	73,553	132,915
10	Premium Deficiency	-	-	-	-	-	-
Incurred Claims <sup>4</sup>							
11	(a) Claims Paid	327,817	291,054	312,539	618,871	577,300	1,236,208
	(b) Change in Outstanding Claims (Including IBNR/IBNER)	79,621	83,956	46,162	114,842	114,842	162,473
12	<b>Total Expense (8+9+10+11)</b>	<b>583,001</b>	<b>542,923</b>	<b>518,648</b>	<b>1,125,924</b>	<b>1,003,696</b>	<b>2,066,968</b>
13	<b>Underwriting Profit/(Loss) (3-12)</b>	<b>(17,836)</b>	<b>(28,314)</b>	<b>(16,091)</b>	<b>(47,150)</b>	<b>(50,751)</b>	<b>(86,948)</b>
14	Provisions for doubtful debts (including bad debts written off)	-	-	-	-	-	-
15	Provisions for diminution in value of investments	-	-	-	-	-	-
16	<b>Operating Profit/(Loss) (6-12)</b>	<b>75,266</b>	<b>65,413</b>	<b>66,417</b>	<b>140,679</b>	<b>116,564</b>	<b>226,692</b>
Appropriations							
17	(a) Transfer to Profit and Loss A/c	75,266	65,413	66,417	140,679	116,564	226,692
	(b) Transfer to Reserves	-	-	-	-	-	-
<b>NON-OPERATING RESULTS</b>							
Income in shareholders' account (a+b+c):							
18	(a) Transfer from Policyholders' Fund	75,266	65,413	66,417	140,679	116,564	226,692
	(b) Income from investments	31,875	31,674	27,548	63,549	52,838	100,482
	(c) Other income	93	844	5	937	9	5,939
19	Expenses other than those related to insurance business	2,235	1,400	2,089	3,635	3,684	5,620
20	Provisions for doubtful debts (including bad debts written off)	452	6	223	458	(291)	(584)
21	Provisions for diminution in value of investments <sup>5</sup>	(3,180)	(2,846)	(243)	(6,026)	(3,282)	(4,054)
22	<b>Total Expense (19+20+21)</b>	<b>(493)</b>	<b>(1,440)</b>	<b>2,069</b>	<b>(1,933)</b>	<b>111</b>	<b>982</b>
23	<b>Profit / (Loss) before extraordinary items (18-22)</b>	<b>107,727</b>	<b>99,371</b>	<b>91,901</b>	<b>207,098</b>	<b>169,300</b>	<b>332,131</b>
24	Extraordinary Items	-	-	-	-	-	-
25	<b>Profit/ (Loss) before tax (23-24)</b>	<b>107,727</b>	<b>99,371</b>	<b>91,901</b>	<b>207,098</b>	<b>169,300</b>	<b>332,131</b>
26	Provision for tax	25,773	24,663	22,506	50,436	41,868	81,302
27	<b>Profit / (Loss) after tax (PAT)</b>	<b>81,954</b>	<b>74,708</b>	<b>69,395</b>	<b>156,662</b>	<b>127,432</b>	<b>250,829</b>
<b>Dividend per share (₹) (Nominal Value ₹ 10 per share)<sup>6</sup></b>							
28	(a) Interim Dividend	-	-	-	-	-	5.50
	(b) Final Dividend	-	7.00	-	7.00	6.00	6.00
29	<b>Profit / (Loss) carried to Balance Sheet</b>	<b>797,832</b>	<b>715,878</b>	<b>579,723</b>	<b>797,832</b>	<b>579,723</b>	<b>675,906</b>
30	Paid up equity capital	49,747	49,664	49,469	49,747	49,469	49,573
31	Reserve & Surplus (Excluding Revaluation Reserve)	1,526,327	1,432,722	1,269,541	1,526,327	1,269,541	1,380,737
32	Share Application Money Pending Allotment	187	571	275	187	275	25
33	Fair Value Change Account and Revaluation Reserve	84,371	132,579	166,437	84,371	166,437	68,074
34	Borrowings	-	-	-	-	-	-
<b>Total Assets:</b>							
(a) Investments:							
	- Shareholders' Fund	1,505,344	1,430,434	1,284,505	1,505,344	1,284,505	1,372,551
	- Policyholders' Fund	4,114,635	4,114,901	3,871,194	4,114,635	3,871,194	3,978,226
	(b) Other Assets (Net of current liabilities and provisions)	(3,959,347)	(3,929,799)	(3,669,977)	(3,959,347)	(3,669,977)	(3,852,368)
<b>Analytical Ratios<sup>7</sup>:</b>							
(i)	Solvency Ratio <sup>7a</sup>	2.73	2.70	2.65	2.73	2.65	2.69
(ii)	Expenses of Management Ratio <sup>7b</sup>	31.9%	27.8%	29.8%	29.7%	28.2%	30.8%
(iii)	Incurred Claim Ratio	72.1%	73.0%	71.4%	72.5%	72.6%	70.6%
(iv)	Net Retention Ratio	75.3%	69.7%	69.6%	72.3%	68.5%	73.5%
(v)	Combined Ratio	105.1%	102.9%	104.5%	104.0%	103.2%	102.8%
(vi)	Earning per share (₹)						
	(a) Basic and diluted EPS before extraordinary items (net of tax expense) for the period <sup>8</sup>	Basic: ₹ 16.49 Diluted: ₹ 16.35	Basic: ₹ 15.06 Diluted: ₹ 14.92	Basic: ₹ 14.05 Diluted: ₹ 13.88	Basic: ₹ 31.55 Diluted: ₹ 31.27	Basic: ₹ 25.83 Diluted: ₹ 25.54	Basic: ₹ 50.74 Diluted: ₹ 50.25
	(b) Basic and diluted EPS after extraordinary items (net of tax expense) for the period <sup>8</sup>	Basic: ₹ 16.49 Diluted: ₹ 16.35	Basic: ₹ 15.06 Diluted: ₹ 14.92	Basic: ₹ 14.05 Diluted: ₹ 13.88	Basic: ₹ 31.55 Diluted: ₹ 31.27	Basic: ₹ 25.83 Diluted: ₹ 25.54	Basic: ₹ 50.74 Diluted: ₹ 50.25
(vii)	NPA ratios:						
	(a) Gross and Net NPAs	-	-	-	-	-	-
	(b) % of Gross & Net NPAs	-	-	-	-	-	-
(viii)	Yield on Investments <sup>9</sup> :						
	(a) Without unrealised gains <sup>10</sup>	2.19%	2.32%	2.19%	4.55%	4.45%	8.42%
	(b) With unrealised gains <sup>10,11</sup>	0.46%	3.60%	3.63%	4.08%	6.95%	9.44%
(ix)	Public shareholding						
	(a) No. of shares	241,914,941	241,085,490	239,141,545	241,914,941	239,141,545	240,175,799
	(b) Percentage of shareholding	48.63%	48.54%	48.34%	48.63%	48.34%	48.40%
	(c) % of Government holding	-	-	-	-	-	-
	(in case of public sector insurance companies)	-	-	-	-	-	-

**Footnotes:**

- Net of reinsurance (Including Excess of Loss Reinsurance).
- Including capital gains, net of amortisation and losses.
- Commission is net of commission received on reinsurance cession.
- Incurred Claim disclosed is net of Reinsurance
- Includes reversal in Provisions for diminution in value of investments amounting to ₹ 3,180 Lakhs and ₹ 6,026 Lakhs pursuant to sale of the underlying securities / receipt against the securities during the quarter ended and year to date ended September 30, 2025 respectively (for the quarter ended June 30, 2025 ₹ 2,846 Lakhs and for the quarter and year to date ended September 30, 2024 ₹ 243 Lakhs and ₹ 3,282 Lakhs respectively and for the year ended March 31, 2025 ₹ 8,430 Lakhs).
- Dividend is recognised in the period in which it is approved as prescribed by MCA
- Analytical ratios have been calculated as per definition given in IRDAI analytical ratios disclosures.
- The Solvency has been computed at the last day of the period.
- The Expenses of Management has been computed on the basis of Gross Direct Premium
- Not annualised
- Yield on investments is computed excluding Investment income from Pools
- Excludes unrealised gains or losses on real estate and unlisted equity
- Yield on investments with unrealised gains is computed using the modified Dietz method
- The computation is based on time weighted average book value.



## Annexure-II

[Pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with IRDAI Circular reference : IRDA/F&amp;A/CIR/LFTD/027/01/2017 dated 30.01.2017]

Segment1 Reporting for the Quarter and year to date ended September 30, 2025

(₹ in lakhs)

Sl. No.	Particulars	3 months ended / As at			Year to date ended / As at		Year ended / As at
		September 30, 2025	June 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024	March 31, 2025
		Audited	Audited	Audited	Audited	Audited	Audited
1	<b>Segment Income:</b>						
	(A) Fire						
	Net Premium Earned	18,173	14,168	18,237	32,341	31,256	65,144
	Income from Investments	5,322	5,668	4,962	10,990	10,583	19,724
	Other Income	(24)	3	(351)	(21)	(659)	(422)
	(B) Marine						
	Net Premium Earned	15,707	14,484	15,170	30,191	28,912	60,739
	Income from Investments	1,409	1,401	1,319	2,810	2,517	4,283
	Other Income	46	(56)	(470)	(10)	(408)	160
	(C) Health including Personal Accident*						
	(i) Health Retail						
	Net Premium Earned	50,371	45,094	33,497	95,465	64,823	138,694
	Income from Investments	3,741	3,755	3,351	7,496	6,389	12,115
	Other Income	48	38	72	86	85	136
	(ii) Health Group, Corporate						
	Net Premium Earned	154,259	143,403	134,621	297,662	264,989	562,426
	Income from Investments	10,488	11,085	9,914	21,573	20,051	35,018
	Other Income	1,059	279	(2,071)	1,338	(1,862)	(2,766)
	(iii) Health Government Business						
	Net Premium Earned	128	203	89	331	150	401
	Income from Investments	25	38	51	63	82	69
	Other Income	1	-	-	1	-	-
	(D) Miscellaneous						
	(i) Miscellaneous Retail						
	Net Premium Earned	3,407	3,025	2,093	6,432	4,091	8,567
	Income from Investments	769	830	773	1,599	1,528	2,859
	Other Income	3	2	4	5	5	9
	(ii) Miscellaneous Group, Corporate						
	Net Premium Earned	28,230	25,233	22,522	53,463	43,748	96,626
	Income from Investments	5,065	5,489	4,834	10,554	9,756	17,967
	Other Income	(70)	(3)	287	(73)	574	45
	(E) Crop Insurance						
	Net Premium Earned	22,038	509	28,103	22,547	31,151	42,454
	Income from Investments	1,071	644	519	1,715	986	2,221
	Other Income	25	-	39	25	41	39
	(F) Motor						
	Net Premium Earned	272,852	267,490	248,225	540,342	483,825	1,004,969
	Income from Investments	62,003	65,364	58,902	127,367	117,190	221,333
	Other Income	2,121	190	373	2,311	457	849
2	Premium Deficiency						
	(A) Fire	-	-	-	-	-	-
	(B) Marine	-	-	-	-	-	-
	(C) Health including Personal Accident*						
	(i) Health Retail	-	-	-	-	-	-
	(ii) Health Group, Corporate	-	-	-	-	-	-
	(iii) Health Government Business	-	-	-	-	-	-
	(D) Miscellaneous						
	(i) Miscellaneous Retail	-	-	-	-	-	-
	(ii) Miscellaneous Group, Corporate	-	-	-	-	-	-
	(E) Crop Insurance	-	-	-	-	-	-
	(F) Motor	-	-	-	-	-	-
3	<b>Segment Underwriting Profit / (Loss):</b>						
	(A) Fire	10,372	5,480	12,574	15,852	19,291	59,029
	(B) Marine	(4,713)	(2,922)	(3,164)	(7,635)	(5,596)	(5,163)
	(C) Health including Personal Accident*						
	(i) Health Retail	167	(12,249)	(7,015)	(12,082)	(11,649)	(20,849)
	(ii) Health Group, Corporate	(9,699)	(10,299)	(14,300)	(19,998)	(25,800)	(59,968)
	(iii) Health Government Business	672	(44)	(60)	628	(55)	(74)
	(D) Miscellaneous						
	(i) Miscellaneous Retail	582	508	1,174	1,090	1,809	956
	(ii) Miscellaneous Group, Corporate	(2,294)	1,229	5,236	(1,065)	3,309	13,229
	(E) Crop Insurance	(5,751)	(413)	(1,313)	(6,164)	(1,935)	1,313
	(F) Motor	(7,172)	(10,604)	(9,223)	(17,776)	(30,125)	(75,421)



(₹ in lakhs)

Sl. No.	Particulars	3 months ended / As at			Year to date ended / As at		Year ended / As at
		September 30, 2025	June 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024	March 31, 2025
		Audited	Audited	Audited	Audited	Audited	Audited
4	<b>Segment Operating Profit / (Loss):</b>						
	(A) Fire	15,670	11,151	17,185	26,821	29,215	78,331
	(B) Marine	(3,258)	(1,577)	(2,315)	(4,835)	(3,487)	(720)
	(C) Health including Personal Accident*						
	(i) Health Retail	3,957	(8,456)	(3,592)	(4,499)	(5,175)	(8,598)
	(ii) Health Group, Corporate	1,848	1,064	(6,459)	2,912	(7,612)	(27,715)
	(iii) Health Government Business	695	(4)	(9)	691	27	(4)
	(D) Miscellaneous						
	(i) Miscellaneous Retail	1,351	1,341	1,952	2,692	3,343	3,824
	(ii) Miscellaneous Group, Corporate	2,702	6,714	10,360	9,416	13,640	31,241
	(E) Crop Insurance	(4,653)	230	(757)	(4,423)	(909)	3,572
	(F) Motor	56,954	54,950	50,052	111,904	87,522	146,761
5	<b>Segment Technical Liabilities:</b>						
	<b>Unexpired Risk Reserve - Net</b>						
	(A) Fire	52,243	54,951	52,196	52,243	52,196	40,007
	(B) Marine	21,945	22,981	21,539	21,945	21,539	15,127
	(C) Health including Personal Accident*						
	(i) Health Retail	109,503	106,641	99,511	109,503	99,511	109,364
	(ii) Health Group, Corporate	308,493	318,292	300,653	308,493	300,653	270,881
	(iii) Health Government Business	499	289	244	499	244	183
	(D) Miscellaneous						
	(i) Miscellaneous Retail	26,206	27,069	26,697	26,206	26,697	27,382
	(ii) Miscellaneous Group, Corporate	81,148	84,262	80,278	81,148	80,278	79,755
	(E) Crop Insurance	4,912	1	5,209	4,912	5,209	1
	(F) Motor	506,600	530,924	482,207	506,600	482,207	555,267
	<b>Outstanding Claims Reserves Including IBNR &amp; IBNER - Gross</b>						
	(A) Fire	363,319	356,909	391,369	363,319	391,369	342,257
	(B) Marine	111,776	106,611	106,711	111,776	106,711	102,192
	(C) Health including Personal Accident*						
	(i) Health Retail	50,942	45,486	40,560	50,942	40,560	38,442
	(ii) Health Group, Corporate	186,047	176,994	169,117	186,047	169,117	157,054
	(iii) Health Government Business	7,560	8,377	6,843	7,560	6,843	8,207
	(D) Miscellaneous						
	(i) Miscellaneous Retail	12,271	11,046	8,843	12,271	8,843	10,382
	(ii) Miscellaneous Group, Corporate	398,771	364,628	328,898	398,771	328,898	330,499
	(E) Crop Insurance	177,819	152,524	203,858	177,819	203,858	215,397
	(F) Motor	2,154,493	2,116,026	1,984,467	2,154,493	1,984,467	2,044,023

**Footnote:**

- Segments include : (A) Fire, (B) Marine, (C) Health including Personal Accident - (i) Health Retail, (ii) Health Group, Corporate and (iii) Health Government Business, (D) Miscellaneous - (i) Retail, (ii) Group / Corporate, (E) Crop Insurance, (F) Motor
- \* includes Travel Insurance



**Other Disclosures\***  
**Status of Shareholders Complaints for the quarter ended September 30, 2025**

Sr No	Particulars	Number
1	No. of Investor complaints pending at the beginning of period	0
2	No. of Investor complaints during the period	0
3	No. of Investor complaints disposed off during the period	0
4	No. of Investor complaints remaining unresolved at the end of the period	0

\* The above disclosure is not required to be audited.



Notes forming part of Annexure I and Annexure II

- 1 The above audited financial results of the ICICI Lombard General Insurance Company Limited (the Company) for the quarter and half year ended September 30, 2025 were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at its Meeting held on October 14, 2025.
- 2 The above audited financial results were audited by the joint statutory auditors, Walker Chandiook & Co LLP, Chartered Accountants and PKF Sridhar & Santhanam LLP, Chartered Accountants who have issued an unmodified opinion on these financial results.
- 3 Refer Enclosure - I for Balance Sheet.
- 4 Refer Enclosure - II for Receipt and Payment account.
- 5 During the quarter and half year ended September 30, 2025, the Company has allotted 829,451 equity shares and 1,739,142 equity shares respectively of face value of ₹ 10 each pursuant to exercise of employee stock options and employee stock units granted. (For the quarter and year to date ended September 30, 2024, 1,470,220 equity shares and 2,006,928 equity shares respectively allotted and for the year ended March 31, 2025, 3,041,182 equity shares allotted of face value of ₹ 10 each).
- 6 The Board of Directors has declared an interim dividend of ₹ 6.50 per equity share of face value of ₹ 10 each at its meeting held on October 14, 2025.
- 7 In accordance with the IRDAI (Actuarial, Finance and Investment Functions of Insurers) Regulation, 2024 and Master Circular thereon dated May 17, 2024, with effect from October 1, 2024, the Company has given effect to recognise gross written premium on a 1/n basis where "n" denotes the policy duration and commissions paid only on such recorded gross written premium for applicable long term products. This has resulted in a decrease in Gross Premium Written by ₹ 36,078 lakhs & ₹ 68,052 lakhs respectively for the quarter and half year ended September 30, 2025, also resulted in decrease of commissions & brokerage (net) and consequently, increase in operating profit/(loss) by ₹ 1,433 lakhs & ₹ 3,171 lakhs respectively for the quarter and half year ended September 30, 2025. This resulted in the increase in Profit / (Loss) after tax by ₹ 1,092 lakhs & ₹ 2,399 lakhs respectively for the quarter and half year ended September 30, 2025. The combined ratio on "n basis" for the quarter and half year ended September 30, 2025 is 103.9% and 103.0% respectively and 102.6% for the year ended 31st March 2025.
- 8 Figures of the previous period have been re-grouped wherever necessary, to conform to the current year presentation.
- 9 In view of the seasonality of Industry, the financial results for the quarters are not indicative of full year's expected performance.
- 10 In accordance with requirements of IRDAI circular no. IRDAI/F&A/CIR/MISC/256/09/2021 dated September 30, 2021 on Public Disclosures by Insurers, the Company will publish the financials on the company's website latest by October 29, 2025.



For and on behalf of the Board

**Sanjeev Mantri**  
Managing Director & CEO  
(DIN : 07192264)

Mumbai  
October 14, 2025

**ICICI Lombard General Insurance Company Limited**

CIN: L67200MH2000PLC129408

Registered Office Address: ICICI Lombard House, 414, Veer Savarkar Marg,  
Near Siddhivinayak Temple, Prabhadevi, Mumbai-400025, Maharashtra  
IRDAI Registration No. 115 dated August 3, 2001**Balance Sheet  
As at September 30, 2025**

(₹ in lakhs)

	At September 30, 2025	At March 31, 2025
<b>Sources of funds</b>		
Share capital	49,747	49,573
Share application money-pending allotment	187	25
Reserves and Surplus	1,526,327	1,380,737
Fair value change account		
Shareholders funds	23,405	18,182
Policyholders funds	60,966	49,892
Borrowings	-	-
<b>Total</b>	<b>1,660,632</b>	<b>1,498,409</b>
<b>Application of funds</b>		
Investments - Shareholders	1,505,344	1,372,551
Investments - Policyholders	4,114,635	3,978,226
Loans	-	-
Fixed assets	84,319	80,200
Deferred tax asset	25,405	16,905
Current assets		
Cash and bank balances	35,220	8,757
Advances and other assets	1,631,694	1,457,864
<b>Sub-Total (A)</b>	<b>1,666,914</b>	<b>1,466,621</b>
Deferred Tax Liability (Net)	-	-
Current liabilities	4,601,598	4,286,423
Provisions	1,134,387	1,129,671
<b>Sub-Total (B)</b>	<b>5,735,985</b>	<b>5,416,094</b>
<b>Net current assets (C) = (A - B)</b>	<b>(4,069,071)</b>	<b>(3,949,473)</b>
Miscellaneous expenditure (to the extent not written off or adjusted)	-	-
Debit balance in profit and loss account	-	-
<b>Total</b>	<b>1,660,632</b>	<b>1,498,409</b>



For and on behalf of the Board

Sanjeev Mantri  
Managing Director & CEO  
(DIN : 07192264)

Mumbai  
October 14, 2025



**ICICI Lombard General Insurance Company Limited**

IRDAI Registration No. 115 dated August 3, 2001

CIN: L67200MH2000PLC129408

Registered Address: ICICI Lombard House, 414, Veer Savarkar Marg, Near Siddhivinayak Temple, Prabhadevi Mumbai-400025, Maharashtra

**Receipts & Payment Account (Cashflow)**

(₹ in lakhs)

**Direct basis**

For the half year ended September 30, 2025

Half year ended  
September 30, 2025Half year ended  
September 30, 2024**A CASH FLOW FROM OPERATING ACTIVITIES**

1	- Premium received from policyholders, including advance receipts	1,564,054		1,430,002
2	- Other receipts-miscellaneous receipts	1,936		921
3	- Receipt / (payment) from/to re-insurer net of commissions & claims recovery	(76,464)		(110,438)
4	- Receipt / (payment) from / to co-insurer net of claims recovery	74,907		60,307
5	- Payments of claims (net of salvage)	(780,486)		(716,782)
6	- Payments of commission and brokerage	(320,916)		(308,179)
7	- Payments of other operating expenses <sup>2</sup>	(163,436)		(162,815)
8	- Preliminary and preoperative expenses	-		-
9	- Deposits, advances & staff loans (net)	(63,210)		(33,362)
10	- Income tax paid (net)	(36,394)		(42,188)
11	- Goods and service tax paid	(154,045)		(134,191)
12	- Other Payments	-		-
13	- Cash flows before extraordinary items		45,946	(16,725)
14	- Cash flows from extraordinary operations		-	-
15	<b>Net cash from operating activities</b>		<b>45,946</b>	<b>(16,725)</b>

**B CASH FLOW FROM INVESTING ACTIVITIES**

1	- Purchase of fixed assets (including capital advances)	(12,876)		(11,510)
2	- Proceeds from sale of fixed assets	59	(12,817)	29
				(11,481)
3	- Purchase of investments	(1,163,512)		(784,052)
4	- Loans disbursed	-		-
5	- Sales of investments	1,049,780		629,236
6	- Repayments received	-		-
7	- Rents/interests/dividends received	169,274		159,518
8	- Investments in money market instruments & in liquid mutual fund (net)	(58,629)		11,377
9	- Expenses related to investments	-		-
10	- Other (Deposit received on leasing of premises)	-	(3,087)	-
11	<b>Net cash from investing activities</b>		<b>(15,904)</b>	<b>4,598</b>

**C CASH FLOW FROM FINANCING ACTIVITIES**

1	- Proceeds from issuance of share capital / application money (including share premium & net of share issue expenses)	20,877		22,794
2	- Proceeds from borrowing	-		-
3	- Repayments of borrowing	-		(3,500)
4	- Interest / Dividends paid	(34,733)		(29,954)
5	<b>Net cash from financing activities</b>		<b>(13,856)</b>	<b>(10,660)</b>

**D Effect of foreign exchange rates on cash and cash equivalents, net**

E	Net increase/(decrease) in cash and cash equivalents		16,186	(22,787)
1	Cash and cash equivalents at the beginning of the year		8,662	33,364
2	Cash and cash equivalents at end of the period <sup>1</sup>		24,848	10,577

<sup>1</sup> Cash and cash equivalent at the end of the period includes short term deposits of ₹ 2,534 lakh (previous year: ₹ 1,019 lakh) balances with banks in current accounts ₹ 21,152 lakh (previous year: ₹ 8,375 lakh) and cash including cheques and stamps in hand amounting to ₹ 1,162 lakh (previous year: ₹ 1,184 lakh)

Reconciliation between Cash and Cash Equivalents as per Balance Sheet and Receipts and Payments Statement.

Particulars	As at September 30, 2025	As at September 30, 2024
Cash and Bank Balances as per Schedule 11	35,220	10,670
Less: Unpaid Dividend	(20)	(20)
Less: Deposits under lien to Banks for issuance of Bank Guarantee	(343)	(73)
Less: Bank balance earmarked as per Cross Broader Reinsurers as per Master Circular on Reinsurance, 2024.	(10,009)	-
Cash and cash equivalents as per Receipts and Payment account	24,848	10,577

<sup>2</sup> Includes payments towards Corporate Social Responsibility of ₹ 1,953 lakh (previous year: ₹ 922 lakh).

The above Receipts & Payments Account has been prepared as prescribed by Insurance Regulatory and Development Authority of India (Actuarial, Finance and Investment Functions of Insurers) Regulations, 2024 under the 'Direct method' in accordance with Accounting Standard 3 on Cash Flow Statements notified under the Section 133 of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2021.

Mumbai  
October 14, 2025



For and on behalf of the Board

Sanjeev Mantri  
Managing Director & CEO  
(DIN : 07192264)

